DGAP-News

Sangui BioTech International Inc.: * SastoMed enters into sales agreements for Southeast Asia, Poland and Russia; Firm purchase commitments agreed

DGAP-News: Sangui BioTech International Inc. / Key word(s): Expansion
Sangui BioTech International Inc.: * SastoMed enters into sales agreements
for Southeast Asia, Poland and Russia; Firm purchase commitments agreed

01.11.2016 / 16:05
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------


Sangui BioTech:
- SastoMed enters into sales agreements for Southeast Asia, Poland and
Russia

- Firm purchase commitments agreed

Witten - November 01, 2016

SastoMed GmbH, to which Sangui BioTech GmbH has licensed the worldwide
distribution rights for the wound spray Granulox, concluded a
comprehensive licensing and sales agreement for eight Southeast Asian
States with Zuellig Pharma, Singapure (www.zuelligpharma.com) one of the
world's leading service providers of the pharmaceuticals. Zuellig Pharma is
responsible for market launch and distribution of Granulox in the
territories of HongKong, Singapore, Thailand, Malaysia, Taiwan, Vietnam,
Indonesia and the Philippines. In addition to the complete processing and
financing of admission in the individual territories, Zuellig Pharma has
committed itself to the purchase of significant quantities of Granulox
within the next five years. Furthermore, two high - performance
distribution partners could be bound: Hexanova Sp.z.o.o. for Poland
(www.hexanova.pl) and MDP Group for Russia (www.mdp-group.net). In both
cases, minimum purchase commitments were also been agreed upon.

"With these agreements, we have succeeded in pushing forward into new
dimensions. Inside the newly acquired sales areas, more than half a billion
people live. We have now reached an important milestone on our path to
global expansion. In addition to the quantitative dimension, the
qualitative contract value of the agreements was also increased. In the
past five years, Granulox has proven in field that it keeps what it
promises on paper. When granting new territories, we now benefit from the
appreciation Granulox has now gained. For instance, Zuellig Pharma for
Southeast Asia and the MDP Group for Russia, two veritable global players
with a corresponding sales force and financial strength, could be obtained
for Granulox. Both partners have committed themselves to realize the
necessary regulatory approvals and subsequent market launch of Granulox in
the respective territories. Guaranteed purchase commitments were agreed
with both partners. The annual minimum purchase quantities fixed within the
next five-year period up to 2021 are based on the time-staggered progress
of the product launches expected by Zuellig Pharma and MDP Group. Starting